Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035555 · ClinicalTrials.gov registry record · Phase 2
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT00035555 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 230 participants.
The verdict
NCT00035555, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mellitus).
Interventions
- DRUG Cyclosporine
- DRUG Mycophenolate mofetil (MMF)
- DRUG Belatacept
- DRUG Corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2001-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035555
The ClinicalTrials.gov registry entry for NCT00035555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclosporine is the first listed.
NCT00035555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035555 about?
NCT00035555 is a clinical study titled "Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney". The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mell...
What is the current status of trial NCT00035555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2001-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00035555?
The interventions under investigation include: Cyclosporine (DRUG), Mycophenolate mofetil (MMF) (DRUG), Belatacept (DRUG), Corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00035555?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.